CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract
- 1 January 1997
- journal article
- review article
- Published by Wiley in Molecular Reproduction and Development
- Vol. 46 (1) , 71-74
- https://doi.org/10.1002/(sici)1098-2795(199701)46:1<71::aid-mrd11>3.0.co;2-6
Abstract
The expression and function of CSF‐1 and its receptor were studied in tumors of the human breast, ovary, and endometrium. CSF‐1 and its receptor, initially implicated as essential to normal monocyte development and trophoblastic implantation, have been more recently shown to be expressed by carcinomas of the breast and other epithelia of the female reproductive tract where activation of the receptor by ligand produced either by the tumor cells or by stromal elements stimulates tumor cell invasion by a urokinase‐dependent mechanism. Breast carcinomas express wild‐type CSF‐1 receptors (CSF‐1R) at levels comparable to those observed in trophoblast and monocytes. Ovarian and endometrial carcinomas express significantly lower levels of wild‐type, functional CSF‐1Rs, while ovarian carcinomas also express unusual transcripts that diverge from the wild‐type CSF‐1R transcript in their 5′ extracellular domain sequences. Tumor cell expression of CSF‐1R is under the control of several steroid hormones (glucocorticoids and progestins) and the binding of several bHLH transcription factors, while tumor cell expresion of CSF‐1 appears to be regulated by other hormones, some of which are involved in normal lactogenic differentiation. In addition, tumor cells often produce CSF‐1 at such high levels that the cytokine spills into the extracellular fluid and circulation. Measurements of circulating levels of CSF‐1 have proved useful in patients with ovarian, endometrial, and breast carcinoma both for disease detection and monitoring of response to therapy. CSF‐1 and its receptor appear to be an important receptor/ligand pair in the biology of breast cancers and tumors of the female reproductive tract where they may regulate functions similar to those they control during macrophage activation and placental implantation. Mol Reprod Dev 46:71–74, 1997.Keywords
This publication has 8 references indexed in Scilit:
- Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: Comparison with CA 125 and the aminoterminal propeptide of type III procollagenAmerican Journal of Obstetrics and Gynecology, 1995
- The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancerCancer, 1995
- Co‐expression of M‐CSF transcripts and protein, FMS (M‐CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovaryThe Journal of Pathology, 1994
- Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survivalAmerican Journal of Obstetrics and Gynecology, 1993
- Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells?Journal of Cellular Biochemistry, 1990
- The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patientsInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasmsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomasInternational Journal of Radiation Oncology*Biology*Physics, 1988